Ultimately, this work brings us closer to understanding why outcomes differ between men and women – and to developing more personalised, effective treatments for all patients with AML.

More from us here ⬇️

By ruling out a previously plausible explanation, the research helps focus efforts on more promising areas – from drug metabolism to immune responses – and highlights the importance of considering sex as a biological variable in future AML research and clinical trial design.

The study found that while AML cells express high levels of androgen receptors, these receptors don’t appear to influence how the cancer grows or responds to treatment. Instead, inflammation and immune signalling may play a bigger role.

In addition to preventing the need for amputations, this new treatment combination could help stop cancer spreading and even prime treatment-resistant tumours to respond to immunotherapy.

Read more ⬇️

Our researchers showed that delivering a cancer-fighting virus alongside isolated limb perfusion triggered a whole-body immune response rather than just a localised one in the affected limb. They also found this approach to be well-tolerated and, for some patients, very effective.

Dr Amin Mirza shares how these complementary technologies help our scientists to characterise new compounds, understand how they interact with biological targets and identify those with the potential to become treatments.

From weighing molecules with extraordinary precision to visualising their atomic structures, our scientists are harnessing cutting-edge chemical analysis tools to accelerate drug discovery from lab bench to bedside.

Read more about Sir Bob Champion's incredible work here ⬇️

@helink.bsky.social, Chief Executive of the ICR said,
“We warmly congratulate Bob on this well-deserved honour and thank him for his generous support over the years - both in raising vital funds and championing the importance of our life-changing work.”

Soft tissue sarcomas have historically been very difficult to treat. However, this new research suggests that by exploiting the cancer’s own resistance evolutions, we may be able to steer it towards drug-sensitive states, making treatment more effective.

Read more from the ICR ⬇️

Only bowel cancer is rising faster in younger adults. Screening may be helping older adults avoid it.

More in @annalsofim.bsky.social

Read how Emily’s work is advancing adaptive trials and patient-reported outcomes in early-phase cancer studies ⤵️

At the ICR, statisticians such as PhD student Emily Alger, @mle-alger.bsky.social are building on those methods to design smarter, more patient-centred clinical trials – ensuring that data leads to better decisions and better outcomes for patients.

The COVID-19 pandemic showed how adaptive statistical designs accelerate the discovery of life-saving treatments. These principles commonly used in cancer research, continue to shape how we test new therapies today.